This program was originally presented as a Satellite Symposium during
the 2007 Annual Meeting of the American College of Clinical Pharmacy.

 

This symposium is your compass for navigating your career in the right direction.

Target Audience Program Agenda Program Overiew Educational Objectives Speaker Biographies Disclosure of Financial Relationships With Any Commerical Interest Disclosure of Potential Conflicts of Interests Acknowledgement of Commerical Support Accreditation Statement Statement of Credit View the Sessions     Target Audience This interactive program is designed for pharmacists and other health care professionals interested in therapeutic advances in the treatment of patients with cancer.   Program Agenda Welcome and Introductions, Activity Pretest via Audience-Interactive Questions Susan Goodin Rationale for the Development of Targeted Agents: Improving Specificity, Efficacy, and Safety of Cancer Therapy D. Ross Camidge Epidermal Growth Factor Inhibitors: Current Clinical Status and New Developments Deborah A. Frieze Current Status of Antiangiogenesis Agents: Administration and Safety Susan Goodin Current Status and Future Directions of HER2-Targeted Agents: Focus on Safety Laura Boehnke Michaud Panel Discussion  Back to top Program Overview Molecularly targeted agents have demonstrated significant clinical results, and these therapies are now included in the treatment regimens of many patients with solid tumors. Although targeted agents generally do not cause the serious and sometimes life- threatening toxicities associated with traditional chemotherapy, such as bone marrow suppression, which leads to increased risk of anemia and infection, they are not without side effects that can be severe. Cutaneous events, such as papulopustular rash, are common adverse effects associated with anti– epidermal growth factor receptor (EGFR)-targeted agents. This rash appears to be dose dependent and the etiology is not completely clear. Adverse events occurring with antiangiogenic agents include hypertension, bleeding, impaired wound healing, and thrombosis. A third type of unwanted effect is cardiotoxicity, which can occur not only with HER2-inhibitory agents but also with anthracycline chemotherapeutic agents often used to treat breast cancer, with the greatest risk occurring with concurrent use of these 2 drug classes. As with any new pharmacologic therapy, pharmacists need to understand the mechanism of action, be familiar with potential side effects and drug or food interactions, and participate in research to identify effective interventions. This program will provide participants with an overview of targeted agents for treating cancer, with a focus on issues key for improving patient outcome, including optimal drug administration, nonpharmacologic and pharmacologic management of side effects, and food and drug interactions.   Educational Objectives 1. Compare the mechanisms of action of different classes of targeted agents for treating patients with cancer. 2. Compare and contrast the dosing, route of administration, food and drug interactions, and optimal drug use of the different classes of targeted cancer therapies. 3. Evaluate the risk of patients developing cardiotoxicity upon receiving HER2- targeted cancer therapy as a single agent or in combination with chemotherapy. 4. Describe the etiology, signs, and symptoms of cutaneous toxicities associated with EGFR inhibitors currently used in treating cancer, and evaluate the best methods to manage them. 5. Summarize the signs, symptoms, and risk factors of the common toxicities associated with antiangiogenic cancer therapies and the recommended strategies for managing them.  Back to top Speaker Biographies Susan Goodin, PharmD, FCCP Susan Goodin, PharmD, FCCP, BCOP, is an Associate Professor of Medicine in the Division of Medical Oncology at the University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School in New Brunswick. She is also an Adjunct Associate Professor of Pharmacy Practice and Administration at Rutgers University College of Pharmacy in Piscataway, New Jersey, as well as Director of Pharmaceutical Services, and Co-Director of the Symptom Management–Supportive Care Group at The Cancer Institute of New Jersey, also in New Brunswick. After earning her doctorate in pharmacy from the University of Kentucky College of Pharmacy in Lexington, Dr Goodin completed a Pharmacy Practice Residency at the University of Kentucky Medical Center in Lexington followed by an Oncology Pharmacy Residency at the Lucille P. Markey Cancer Center in conjunction with the University of Kentucky Medical Center. She is a board certified Oncology Pharmacist and is licensed in both New Jersey and Kentucky. Dr Goodin is a member of several professional societies, including the American Society of Health-System Pharmacists (ASHP), the American College of Clinical Pharmacy (ACCP), the American Society of Clinical Oncologists (ASCO), the Hematology Oncology Pharmacy Association (HOPA), and the International Society of Oncology Pharmacy Practice (ISOPP). An active researcher, she has given many presentations throughout the United States, Canada, and Europe; her work has been published in journals such as Journal of Clinical Oncology, Journal of the American Pharmacy Association, The Oncologist, and Cancer, to name a few. She is a reviewer for Clinical Cancer Research, American Journal of Health-System Pharmacy, Drugs, and The Oncologist, and has held a number of editorial positions as well. D. Ross Camidge, MD D. Ross Camidge, MD, is Assistant Professor of Medicine/Oncology at the University of Colorado. After earning a Bachelor of Arts (Hons) degree in Physiological Sciences from Oxford University in the United Kingdom and a Doctorate in Molecular Biology from Cambridge University, Dr Camidge returned to Oxford University to complete a Doctor of Medicine degree and attain a Membership of the Royal College of Physicians in Medicine. His academic honors include the John Scrimgeour Clinical Lectureship Medal and the Anne Hollman Oncology Medal. Dr Camidge is a member of the American Society of Clinical Oncology, the Southwest Oncology Group, the British Medical Association, and the Association of Cancer Physicians in the United Kingdom. He has published numerous articles in journals such as Journal of Clinical Oncology, British Medical Journal, Oncology, and British Journal of Cancer. Dr Camidge is also an author of a chapter in Introduction to the Cellular and Molecular Biology of Cancer. Deborah A. Frieze, PharmD, BCOP Deborah A. Frieze, PharmD, BCOP, is an Oncology/Hematology Clinical Pharmacist at the Seattle Cancer Care Alliance in Seattle, WA, and a Clinical Assistant Professor at the University of Washington School of Pharmacy. After earning a Bachelor of Science degree in Biology from the University of Missouri and a Doctor of Pharmacy from the University of Kansas, Dr Frieze completed a Pharmacy Practice Residency and an Oncology Specialty Residency at the University of Washington Medical Center and Seattle Cancer Care Alliance. Her academic honors include membership in Rho Chi. Dr Frieze is a member of the American College of Clinical Pharmacy, the American Society of Health-System Pharmacy, and the American Society of Clinical Oncology. Additionally, she is a co-author of the Lung Cancer Chapter in the upcoming edition of DiPiro’s Pharmacotherapy. Laura Boehnke Michaud, PharmD, BCOP, FASHP Laura Boehnke Michaud, PharmD, BCOP, FASHP, received her Doctorate of Pharmacy from the University of Kansas and subsequently completed a Pharmacy Practice Residency at the Denver Veterans Affairs Medical Center and a specialty residency in Oncology Pharmacy at the University of Colorado Health Sciences Center in Denver, Colorado. She is also Board Certified in Oncology Pharmacy (BCOP) and is a Fellow of the American Society of Health-Systems Pharmacists (FASHP). Since completion of her training, Dr Michaud has been employed at The University of Texas M. D. Anderson Cancer Center in the Medical Breast Oncology Department as a Clinical Pharmacy Specialist and Manager of Clinical Pharmacy Services. Dr Michaud also holds appointments as Adjunct Assistant Professor of Pharmacy Practice with the University of Houston, College of Pharmacy; Clinical Instructor with the University of Texas, College of Pharmacy; and Clinical Assistant Professor, Target Populations at The University of Texas, School of Nursing. Dr Michaud has published numerous articles and book chapters that have appeared in professional journals such as Journal of Clinical Oncology and American Journal of Hospital Pharmacy, as well as several presentations at the American Society of Clinical Oncology Annual Meetings. Her research interests include pharmacokinetics, side-effect management, and the treatment of breast cancer.   Back to top   Disclosure of Financial Relationships With Any Commercial Interest As a provider accredited by the ACCME, it is the policy of the CBCE to require that everyone who is in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest, and identify and resolve all conflicts of interest prior to the educational activity. The CBCE defines "relevant financial relationships" as any amount occurring within the past 12 months. Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (eg, stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. The CBCE considers relationships of the person involved in the educational activity to include financial relationships of a spouse or partner. Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship(s), the participants must be informed that no relevant financial relationship(s) exists.   Disclosure of Potential Conflicts of Interest The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE activities. Identified conflicts of interest are thoroughly evaluated by the Planning Committee for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations. The CBCE is committed to providing its learners with high-quality, unbiased, and state-of-the-art education.  Back to top   The following faculty member has reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process: Name: Deborah A. Frieze, PharmD, BCOP                           Nature of Financial Relationship: Honoraria Commercial Interest: Amgen Inc.   The following faculty have declared they have no financial relationships that require disclosure: D. Ross Camidge, MD, PhD Susan Goodin, PharmD, FCCP, BCOP Laura Boehnke Michaud, PharmD, BCOP, FASHP   Back to top Acknowledgement of Commercial Support The CBCE gratefully acknowledges the educational grant provided by Genentech BioOncology/OSI Pharmaceuticals, Inc. Accreditation Statement Pharmacists: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. CPE Credit: 2.0 contact hours or 0.200 CEUs   Statement of Credit The Evaluation and Request for Credit Form must be completed and returned to the CBCE following this activity to obtain credit. Participants will receive their statement of credit 4-6 weeks after submission of the form.

Update yourself from top professionals in the field by reviewing sessions now!







Back to top

These sessions require Adobe Flash Player and Adobe Reader to view. If you do not have a recent version of Adobe Flash Player and Adobe Reader , you can download the latest version by clicking on the logos below.
You will need to be connected to the Internet to download.
These sessions are best viewed in Internet Explorer 5.0 or higher.

For technical assistance with these sessions, please contact
Content Management Corporation support: support@cmcgc.com or 1-888-711-1138

Copyright © 2007 American College of Clinical Pharmacy

Powered by Content Management Corporation